



p53-Therapeutics, Inc. Announces New Additions to the Team

[Providence, Rhode Island, September 27, 2026] –p53 Therapeutics, a biotechnology company developing a new class of small-molecule cancer therapeutics, today announced four key additions to its team. The appointments build on the company's recent expansion of its executive leadership and its establishment of global headquarters, laboratory facilities, and collaborative partnerships in Rhode Island.



Roxanne Wood, MPH, Senior Director of Operations, Safety & Compliance

Roxanne Wood, MPH, is an oncology clinical research professional with experience in the development and management of investigator-initiated clinical trials. She has more than 20 years of experience in clinical research, with expertise spanning study operations, regulatory affairs, FDA submissions, clinical trial oversight, quality assurance, and multidisciplinary collaboration.

Roxanne has held a leadership role with the Brown University Oncology Research Group (BrUOG) at Brown University Health, where she has overseen oncology clinical trials from study concept and regulatory submission through enrollment, study completion, and publication. Her work has included supporting investigator-initiated studies, IND/IDE activities, clinical research operations, and partnerships with academic institutions, industry, and healthcare organizations. She holds a Master of Public Health from Brown University and has a particular interest in oncology, clinical research, health equity, and community engagement. Roxanne underscored the importance of building the operational foundation needed to support p53 Therapeutics' next phase of growth. "I'm excited to join p53 Therapeutics at such a pivotal stage of growth. My focus will be on building the operational discipline, safety culture, and compliance infrastructure needed to support the company's development programs, strategic collaborations, and long-term mission to bring meaningful new therapies to patients."

Dinara Ryspayeva, MD, PhD, Medical Director

Dinara Ryspayeva, MD, PhD, is a Visiting Assistant Professor in the Department of Pathology and Laboratory Medicine at Brown University's Legorreta Cancer Center. She is a medical oncologist and translational scientist with more than 20 years of clinical oncology experience and extensive academic and leadership experience in oncology research, clinical trials, and medical education.



Dr. Ryspayeva earned her M.D. from Kyrgyz State Medical Academy and her Ph.D. from the Kharkiv Medical Academy of Postgraduate Education (Ukraine), followed by postdoctoral training at the National Cancer Institute of Ukraine. Prior to joining Brown University, she served as a tenured Associate Professor of Oncology in Ukraine and held senior leadership positions in clinical and scientific research, including Chief Medical Oncologist and Head of the Clinical and Scientific Research Department at LISOD (Israeli Oncological Hospital, Ukraine). She has served as a Principal Investigator and Sub-Investigator in approximately 20 international clinical trials and contributed to the development of Ukraine's state-unified clinical protocol for colorectal cancer. Dinara highlighted the opportunity to help advance a differentiated approach to cancer treatment through rigorous, patient-centered clinical development. "I am thrilled to join p53 Therapeutics at a time when the company is advancing a differentiated approach to cancer treatment. I look forward to helping shape and execute a thoughtful clinical-development strategy centered on rigorous science, patient safety, and the potential to deliver meaningful outcomes for people living with cancer."



Junaid (Jay) Abdulghani, MD, PhD, IND Strategy

Junaid (Jay) Abdulghani, MD, PhD is a physician-scientist and clinical development leader with more than 20 years of experience in oncology drug development and translational research. He has held clinical development and medical leadership roles across biotechnology and pharmaceutical companies, including Novocure, Janssen Pharmaceuticals, and Incyte. His experience spans clinical development strategy, protocol development, medical monitoring, regulatory engagement, biomarker-driven development, and cross-functional leadership. He has also held academic research positions at leading cancer centers, with research focused on cancer biology and the translation of novel therapeutic approaches into clinical development. Junaid emphasized the strength of the company's scientific focus and the potential of its growing pipeline. "p53 Therapeutics is building an exciting pipeline around an important and compelling area of cancer biology. I am eager to work alongside this accomplished

<https://p53-therapeutics.com/>



team to help guide the clinical development of its programs, generate high-quality evidence, and bring promising therapies forward for patients with significant unmet needs.”



Jill Strandberg, PhD candidate at Brown University, Graduate Intern

Jill Strandberg, ScM, is currently a 4th year biomedical engineering (BME) PhD candidate at Brown University. She received her Bachelor’s in BME from the University of Connecticut and her Master of Science in BME from Brown University. She has 7 years of research experience in the cancer biology and immunology fields. At Brown University, her research focuses on mitigating radiation-induced lung injury through modulation of the TRAIL pathway. Jill expressed enthusiasm for contributing her multidisciplinary scientific experience to the company’s translational research efforts.

“I am excited to join p53 Therapeutics and contribute to a team working to advance new treatment options for patients with cancer. This internship offers an invaluable opportunity to apply my background in cancer biology, immunology, and biomedical engineering to meaningful translational research while learning from leaders committed to rigorous science and patient impact.”

The recently added p53-Therapeutics team members are joining an exciting, growing bio-pharmaceutical organization that is addressing a major unmet need in Oncology and Precision Oncology. They will be reporting in their respective roles to the p53-Therapeutics Executive Team that includes CEO Bradley Sander, CMO Emile Youssef, MD, PhD, and Founder/Chairman Wafik S. El-Deiry, MD, PhD, FACP.

Wafik S. El-Deiry, M.D., Ph.D., FACP, Former Inaugural Associate Dean for Oncologic Sciences at the Warren Alpert Medical School and Founding Director of the Legorreta Cancer Center at Brown University commented on the four new additions to p53-Therapeutics and company relocation to Providence, RI in 2026: “We are delighted to welcome these four talented individuals to p53-Therapeutics at an important point in our growth. Their collective expertise across clinical development, operations, patient safety, regulatory compliance, and cutting edge translational research strengthens our advancement of medical science with rigor to help patients with urgency. Each brings deep commitment to our mission of developing innovative small-molecule therapies to have a meaningful impact on the lives of patients with cancer.”

About p53-Therapeutics, Inc.:

The company’s two lead programs, small molecules targeting cancers characterized by *TP53* mutations, are currently being evaluated in Investigational New Drug (IND)-enabling studies. p53-Therapeutics was awarded funding through the Rhode Island New Business Attraction Program to support IND-enabling studies and to facilitate its move to the Rhode Island. The award, provided through the Rhode Island Life Science Hub (RILSH), offers financial support for life sciences companies establishing a presence in Rhode Island. RILSH was established by Rhode Island Governor Daniel McKee and Speaker of the House of Representatives Joseph Shekarchi, in 2023 with a \$45 million investment in the life sciences, and a mandate to create business development opportunities for companies, and develop much-needed wet lab incubator spaces.



p53-Therapeutics is a **Foundational Tenant at Ocean State Labs, powered by Portal Innovations in Providence, Rhode Island.** The company has laboratory space and office space for its workforce and looks forward to becoming part of the vibrant life sciences ecosystem in Rhode Island. The company is collaborating with Provid Pharmaceuticals for large scale drug synthesis as well as numerous analogs of lead compounds in the p53-Therapeutics pipeline.

p53-Therapeutics, Inc. is developing a new class of small molecule cancer therapeutics to effectively bypass mutations in the p53 tumor suppressor gene to treat patients with cancer. *TP53* mutations occur frequently across tumor types. *TP53* is mutated in most human cancers and at an even higher frequency among difficult to treat cancers and in patients that fail first-line therapies. Particularly high mutation rates occur in head and neck, ovarian, colorectal, lung and brain cancer, among others. P53-Therapeutics uses a novel approach with candidate drugs that biochemically and functionally replace this most important cancer suppressor to address therapy resistance in the clinic. The Company is developing molecules to target a broad range of p53-mutated cancers based on compelling pre-clinical safety, efficacy and biomarker data with line of sight to IND filing and strong IP position.